

Regimen Reference Order – THOR – lorlatinib

ARIA: LUNG - [lorlatinib]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Non-Small Cell Lung Cancer Anaplastic Lymphoma Kinase (ALK) - Positive

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ Contact Physician if parameters not met

Pre-treatment Requirements

| Drug | Dose | CCMB Administration Guideline |
|----------------|------|-------------------------------|
| Not Applicable | | |

Treatment Regimen – THOR – lorlatinib

| Drug | Dose | CCMB Administration Guideline |
|---|--------|--|
| lorlatinib | 100 mg | Orally once daily with or without food Swallow whole (Self-administered at home) |
| lorlatinib (LORBRENA®) available dosage strengths: 100 mg and 25 mg tablets Classification: Cytotoxic, Hazardous | | |

REQUIRED MONITORING

Cycle 1

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, glucose, albumin, cholesterol and triglycerides as per Physician Orders
- Lipase
- EKG
- Blood pressure
- Patient weight at each clinic visit

Day 15

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, glucose, albumin, cholesterol and triglycerides as per Physician Orders
- Clinic nurse assessment by medical oncologist nurse for symptom assessment, cholesterol, triglycerides and blood pressure
- Patient weight at each clinic visit

Cycle 2

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, glucose, albumin, cholesterol and triglycerides as per Physician Orders
- EKG
- Blood pressure
- Patient weight at each clinic visit

Cycle 3**Day 1**

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, glucose, albumin, cholesterol and triglycerides as per Physician Orders
- EKG
- Blood pressure
- Patient weight at each clinic visit

Cycle 4 and Onwards

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, glucose, albumin, cholesterol and triglycerides
 - At the physician’s discretion but no less than every 3 months
- Lipase periodically as clinically indicated
- EKG monthly
- Blood pressure monthly
- Patient weight at each clinic visit

Recommended Support Medications

| Drug | Dose | CCMB Administration Guideline |
|---------------|------|-------------------------------|
| None required | | |

INSTRUCTIONS FOR PATIENT

- Inform patient that any new/worsening cough or shortness of breath must be reported and assessed urgently by the medical oncologist or designate (i.e. family practitioner in oncology) because of the risk of interstitial lung disease/pneumonitis
- Patients should be instructed to report CNS effects, including seizures, cognitive changes and negative mood disturbances (including suicidal ideation)
- lorlatinib has potential for significant drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on lorlatinib

ADDITIONAL INFORMATION

- lorlatinib is associated with hypercholesterolemia and hypertriglyceridemia. Support protocols for rosuvastatin and fenofibrate are available under **lorlatinib Support** in the “Lung Cancer” folder if required
- lorlatinib can cause cognitive effects
- lorlatinib can cause hypertension
- lorlatinib can cause rapid onset edema
- lorlatinib can cause PR interval prolongation and atrioventricular (AV) block
- lorlatinib can cause peripheral neuropathy
- lorlatinib will be dispensed by CCMB Pharmacy